AstraZeneca Unveils $3.5 Billion U.S. Expansion, Adding 1,000+ Jobs by 2026

AstraZeneca announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy.

AstraZeneca’s expanding footprint in the US includes, among others:

• A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts
• A next generation manufacturing facility for biologics in Maryland
• Cell therapy manufacturing capacity on the West and East Coasts
• Specialty manufacturing in Texas

Pascal Soriot, Chief Executive Officer, AstraZeneca said: “Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation.”